Cost & Access

What the GHK-CU Costs, Who Sets That Number

Summary

• No price figures on this page: Retail pricing changes faster than any published figure stays true, and no trial has compared two products anyway.

• What the evidence supports: What the evidence supports: three randomized trials in which GHK-Cu was the variable under test, with two showing no objective benefit and one reporting reductions in wrinkle volume and depth. A fourth is underway and has not reported.1,2,45

• Concentration is not value: The measured dose response is biphasic, and in one human trial the lower concentration outperformed the higher.3,4

• Delivery is unresolved: Almost no peptide or copper crossed intact skin in a controlled permeation study using in vitro human skin models.5

• Professional treatment: The one trial testing GHK-Cu as an adjunct to a clinical laser procedure found no objective benefit.2

• Injection: No published human pharmacokinetic data by any route. The rodent systemic safety work used copper-free GHK rather than GHK-Cu.6,7

Why There Are No Prices on This Page

Other pages will give you a figure per milliliter and a comparison table. There are two problems with that.

Retail pricing runs across dozens of brands in several currencies and changes constantly, so any published figure is out of date quickly.

The second problem matters more. A price comparison implies the products being compared differ in what they deliver. No trial has compared two GHK-Cu products against each other, so there is no published basis for saying a more expensive one works better. A comparison table would manufacture a precision the evidence cannot support.

What Does the Money Actually Buy?

A well-characterized molecule with an extensive laboratory record, mixed clinical trials, and an unresolved question about whether it reaches its target.

It is worth being precise about what is and is not established, because the gap between the two is where the pricing sits.

The honest description of a purchase here is that it is a bet on a plausible mechanism with mixed clinical evidence, with a fourth trial underway and unreported. That is not the same as saying it does not work. It is saying that if it works, nobody has yet shown it.

Does a Higher Concentration Justify a Higher Price?

As far as the published dose-response data go, no.

One mapped laboratory curve rises and then falls. Three further observations are consistent with that shape without independently establishing it. No published setting shows a higher concentration performing better:

• Glycosaminoglycan synthesis, the one mapped curve: Explicitly described as biphasic, maximal between 10 to the minus 9 and 10 to the minus 8 molar, returning progressively toward control at higher concentrations.3

• Collagen synthesis: Beginning between 10 to the minus 12 and 10 to the minus 11 molar and maximizing at 10 to the minus 9 molar.4

• Optimal range in culture: Reported by the peptide's discoverer as between 10 and 200 nanograms per milliliter, for copper-free GHK rather than the copper complex.11

• In a human trial: In a randomized study of male pattern hair loss, hair count rose by 71.5 in the 50 mg/ml arm and by 52.6 in the 100 mg/ml arm, against 9.6 in placebo. The lower concentration performed better. That trial tested a complex of 5-aminolevulinic acid with GHK rather than GHK-Cu, so it speaks to the shape of the dose-response rather than to GHK-Cu specifically.12

A premium charged for a higher percentage is therefore a premium charged for a position on the curve that none of the available measurements favors.

Is a Professional Treatment Better Value?

The single relevant trial says no, and it tested exactly that scenario.

The 2006 randomized trial recruited patients undergoing carbon dioxide laser resurfacing, a clinical procedure, and randomized them to post-treatment regimens with or without GHK-Cu. Evaluation used blinded assessors and computer image analysis. The result was no significant difference in resolution of erythema, and no objective improvement in wrinkles or overall skin quality. Patient-reported satisfaction was higher in the GHK-Cu group at p equals 0.04. That endpoint is subjective, and the published abstract does not state whether participants were blinded to their assignment.2

One completed registration on ClinicalTrials.gov is sometimes cited in this context: a Phase 4 study of 27 participants. It was non-randomized, single-group, and unmasked, and the intervention was a HydraFacial treatment system. A copper peptide appears only as one component of a ReGen-GF formulation used within it, alongside Heptapeptide-32, Palmitoyl Tetrapeptide-7 and others. It was not designed to evaluate the peptide and cannot say anything about it.13

There is a reasonable argument for professional delivery that this evidence does not address. In an in vitro skin model, microneedling produced measurable permeation where intact skin produced almost none, so a procedure that breaches the barrier has a mechanistic case that a serum does not.5 That case rests on delivery data measured in laboratory skin models, not on outcome data in people. No trial has tested whether better delivery produces a better clinical result.

What About Buying Powder and Injecting It?

This is where the cost calculation changes category, because the risks stop being financial.

Research-grade powder is generally cheaper per milligram than finished cosmetics, which is the entire appeal. Three things should be weighed against that.

• Nobody can tell you the dose. No human pharmacokinetic data have been published for GHK by any route. The pharmacokinetic work amounts to a 1997 rat experiment, which studied GHK rather than the copper complex. Intravenous GHK was rapidly degraded to the dipeptide histidyl-lysine and eliminated rapidly.6

• The systemic rodent data are not reassuring. A 2002 study describes the tripeptide as a hepatotropic immunosuppressor and reports dose-dependent suppression of immune reactivity across repeated intraperitoneal dosing. That study dosed copper-free GHK, not GHK-Cu, so it describes the peptide rather than the complex sold as a copper product.7 A companion paper reports deteriorated serum biochemistry and dystrophic liver changes at the higher dose.14

• The topical safety data do not transfer. The keratinocyte study that found GHK-Cu non-cytotoxic and non-irritating used cultured cells, not skin on a person.9 It says nothing about systemic exposure.

It is also worth noting what the founding 1980 paper in Nature said about this molecule at nanomolar concentrations across cultured systems: that it produces responses ranging from the stimulation of growth and differentiation to outright toxicity.15

What Should I Ask Before Paying for a Treatment?

Questions that separate a practitioner who has read the literature from one who has read the brochure.

• What human evidence supports this for my goal: A straight answer acknowledges three randomized trials, with two showing no objective benefit and one reporting reductions in wrinkle volume and depth, plus one ongoing Phase 2 wound trial that has not reported.”1,2,16

• How is it getting through my skin: If the answer does not involve breaching the barrier, ask how they reconcile that with the permeation data.5

• Which molecule is in the product: Copper tripeptide-1, palmitoyl GHK and copper-free GHK are different, and evidence for one does not transfer.

• What concentration, and why that one: A considered answer engages with the biphasic dose response rather than treating higher as better.

• What happens if it does not work: Worth asking before a course of treatments rather than after.

What Would Change This Assessment?

One thing, and it has a date attached. A Phase 2 trial of topical GHK-Cu gel against vehicle placebo in standardized punch-biopsy wounds, 60 participants, sponsored by Hudson Biotech, has been recruiting since 2 February 2026 with primary completion scheduled for 14 February 2027.16

It is placebo-controlled and uses a standardized wound, which is more methodological rigour than this compound has received in thirty-four years. If it reports a positive result, the assessment on this page changes. If it reports a positive result, the assessment on this page changes. If it reports null, that will add another null result to a mixed controlled human evidence base.

Sources

Seventeen sources. No price figures or product comparisons appear on this page, because neither can be sourced to a citable record.

1. Bishop JB, Phillips LG, Mustoe TA, VanderZee AJ, Wiersema L, Roach DE, Heggers JP, Hill DP Jr, Taylor EL, Robson MC. A prospective randomized evaluator-blinded trial of two potential wound healing agents for the treatment of venous stasis ulcers. J Vasc Surg. 1992;16(2):251-257. PMID 1495150. pubmed.ncbi.nlm.nih.gov/1495150

2. Miller TR, Wagner JD, Baack BR, Eisbach KJ. Effects of topical copper tripeptide complex on CO2 laser-resurfaced skin. Arch Facial Plast Surg. 2006;8(4):252-259. PMID 16847171. doi.org/10.1001/archfaci.8.4.252

3. Wegrowski Y, Maquart FX, Borel JP. Stimulation of sulfated glycosaminoglycan synthesis by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+. Life Sci. 1992;51(13):1049-1056. PMID 1522753.

4. Maquart FX, Pickart L, Laurent M, Gillery P, Monboisse JC, Borel JP. Stimulation of collagen synthesis in fibroblast cultures by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+. FEBS Lett. 1988;238(2):343-346. PMID 3169264.

5. Li H, Low YS, Chong HP, Zin MT, Lee CY, Li B, Leolukman M, Kang L. Microneedle-Mediated Delivery of Copper Peptide Through Skin. Pharm Res. 2015;32(8):2678-2689. PMID 25690343. doi.org/10.1007/s11095-015-1652-z

6. Endo T, Miyagi M, Ujiie A. Simultaneous determination of glycyl-L-histidyl-L-lysine and its metabolite, L-histidyl-L-lysine, in rat plasma by high-performance liquid chromatography with post-column derivatization. J Chromatogr B Biomed Sci Appl. 1997;692(1):37-42. PMID 9187381.

7. Smakhtin MY, Sever'yanova LA, Konoplya AI, Shveinov IA. Tripeptide Gly-His-Lys is a hepatotropic immunosuppressor. Bull Exp Biol Med. 2002;133(6):586-587. PMID 12447473. doi.org/10.1023/a:1020242127443

8. Trapaidze A, Hureau C, Bal W, Winterhalter M, Faller P. Thermodynamic study of Cu2+ binding to the DAHK and GHK peptides by isothermal titration calorimetry with the weaker competitor glycine. J Biol Inorg Chem. 2012;17(1):37-47. PMID 21898044. doi.org/10.1007/s00775-011-0824-5

9. Li H, Toh PZ, Tan JY, Zin MT, Lee CY, Li B, Leolukman M, Bao H, Kang L. Selected Biomarkers Revealed Potential Skin Toxicity Caused by Certain Copper Compounds. Sci Rep. 2016;6:37664. Open access. PMID 27892491. pmc.ncbi.nlm.nih.gov/articles/PMC5124859

10. Dou Y, Lee A, Zhu L, Morton J, Ladiges W. The potential of GHK as an anti-aging peptide. Aging Pathobiol Ther. 2020;2(1):58-61. Open access. PMID 35083444. pmc.ncbi.nlm.nih.gov/articles/PMC8789089

11. Pickart L. The use of glycylhistidyllysine in culture systems. In Vitro. 1981;17(6):459-466. PMID 7021400.

12. Lee WJ, Sim HB, Jang YH, Lee SJ, Kim DW, Yim SH. Efficacy of a Complex of 5-Aminolevulinic Acid and Glycyl-Histidyl-Lysine Peptide on Hair Growth. Ann Dermatol. 2016;28(4):438-443. Open access. PMID 27489425. pmc.ncbi.nlm.nih.gov/articles/PMC4969472

13. ClinicalTrials.gov. NCT05932732, Trial Assessing the Impact on Facial Skin Quality, Hydration, and Skin Barrier of Three Hydrafacial Treatments in Adults of All Skin Types. Phase 4, 27 participants, completed. Record checked 25 August 2026. clinicaltrials.gov/study/NCT05932732

14. Smakhtin MIu, Konoplia AI, Sever'ianova LA, Shveinov IA. Pharmacological correction of immuno-metabolic disorders with the peptide Gly-His-Lys in hepatic damage induced by tetrachloromethane. Patol Fiziol Eksp Ter. 2003;(2):19-21. Article in Russian; abstract consulted. PMID 12838768.

15. Pickart L, Freedman JH, Loker WJ, Peisach J, Perkins CM, Stenkamp RE, Weinstein B. Growth-modulating plasma tripeptide may function by facilitating copper uptake into cells. Nature. 1980;288(5792):715-717. PMID 7453802. doi.org/10.1038/288715a0

16. ClinicalTrials.gov. NCT07437586, Topical GHK-Cu Gel for Acute Skin Wound Healing. Phase 2, 60 participants, sponsor Hudson Biotech. Recruiting. Start 2 February 2026, primary completion 14 February 2027. Record checked 25 August 2026. clinicaltrials.gov/study/NCT07437586

17. US Food and Drug Administration. Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act. Updated 14 May 2026. Category 1 entry for GHK-Cu except injectable routes, and the stated intention to consult the Pharmacy Compounding Advisory Committee before the end of February 2027. fda.gov/media/94155/download

Not medical advice

GHK-Cu has no FDA approval for any medical indication. FDA's list of bulk drug substances nominated for compounding under section 503A, updated 14 May 2026, places GHK-Cu, except for injectable routes, in Category 1, under evaluation, with an advisory committee review expected before the end of February 2027.17 No therapeutic dose has been established for any of the uses discussed here. Regulators outside the United States were not surveyed for this page. Consult a qualified healthcare provider before acting on anything here.